Reactions Weekly | 2021
Atezolizumab
Abstract
Anti-Hu-antibodies-mediated encephalitis : case report A 47-year-old man developed anti-Hu-antibodies-mediated encephalitis during treatment with atezolizumab for small cell neuroendocrine carcinoma*. The man presented with a complaint of progressively worsening shortness of breath on exertion. Upon presentation, he underwent various investigations. Based on which, he was diagnosed with small cell neuroendocrine carcinoma. Thereafter, he received palliative radiation. He also received four cycles of carboplatin, etoposide and atezolizumab chemotherapy followed by atezolizumab [route and dosage not stated]. For bone metastasis, he received monthly denosumab. During the follow-up visits, he reported worsening of fatigue and chills. At that time, CT scan revealed stable malignancy. Crebrospinal fluid analysis showed high titers of anti-Hu antibodies. In view of stable disease and high anti-Hu antibody titer, he was detected with immune-mediated side effect i.e. anti-Hu-antibodies-mediated encephalitis secondary to atezolizumab [time to reaction onset not stated]. The man then treated with prednisone and showed improvement in his cognition. Thereafter, he continued to receive prednisone.